NEWS

News

Publish Date
2023-10-03 13:54
Heading

NEW REAL-WORLD DATA SHOWS ABBOTT’S FREESTYLE LIBRE® TECHNOLOGY DELIVERS SIGNIFICANT HEALTH BENEFITS FOR PEOPLE WITH TYPE 2 DIABETES

Description

Real-world comparative study in Sweden shows that FreeStyle Libre system use is associated with lower HbA1c levels for people with Type 2 diabetes using insulin therapy.

Reference Page Path
/content/corp/abbott/gb/en/media-center/news/New-Real-World-Data-Shows-Abbotts-FreeStyle-Libre-Technology-Delivers-Significant-Health-Benefits-For-People-with-Type-2-Diabetes

News

Publish Date
2023-07-13 13:54
Heading

NEW UPDATE TO ABBOTT’S FREESTYLE LIBRELINK APP ENABLES PEOPLE USING FREESTYLE LIBRE 2 SYSTEM TO RECEIVE AUTOMATIC GLUCOSE READINGS EVERY MINUTE

Description

Abbott has today announced an update to its FreeStyle LibreLink app, which will allow people who use the FreeStyle Libre 2 system to get real-time minute-by-minute glucose readings automatically displayed on the app.

Reference Page Path
/content/corp/abbott/gb/en/media-center/news/New-Update-to-Abbott-s-FreeStyle-LibreLink-App-Enables-People-Using-FreeStyle-Libre--2-System-to-Receive-Automatic-Glucose-Readings-Every-Minute

News

Publish Date
2023-04-27 14:39
Heading

KEY DIABETES PLAYERS ABBOTT, YPSOMED AND CAMDIAB JOIN FORCES IN THE UK TO OFFER HYBRID CLOSED LOOP SYSTEM WITH MORE AFFORDABLE SENSOR TECHNOLOGY

Description

Abbott today announced that its FreeStyle Libre® 3 sensor – the first continuous glucose monitor (CGM) with readings every minute – is now authorised to work with Ypsomed’s mylife™ YpsoPump and CamDiab's CamAPS FX mobile app in a major step forward for Type 1 diabetes management in the UK.

Reference Page Path
/content/corp/abbott/gb/en/media-center/news/Key-Diabetes-Players-Abbott%2c-Ypsomed-and-CamDiab-Join-Forces-in-the-UK-to-offer-Hybrid-Closed-Loop-System-with-More-Affordable-Sensor-Technology

News

Publish Date
2023-02-22 14:39
Heading

OVER A THIRD OF BRITS IN THE DARK OVER WHEN ANTIBIOTICS ARE NEEDED, NEW ABBOTT SURVEY REVEALS 

Description

A new survey from global healthcare company, Abbott, has found that over a third (37%) of Brits either don’t know or are misinformed as to what illnesses antibiotics can effectively treat. 

Reference Page Path
/content/corp/abbott/gb/en/media-center/news/over-a-third-of-brits-in-the-dark-over-when-antibiotics-are-needed-new-abbott-survey-reveals

News

Publish Date
2023-01-24 14:39
Heading

BRITS LIVING WITH DIABETES FEEL STIGMA AND BIAS IMPACT THEIR ABILITY TO MANAGE THEIR CONDITION

Description

With diabetes prevalence expected to reach almost 5.5 million across the UK by 2030ii, new results from a first-of-its-kind survey by Abbott has identified a clear disconnect between the perceptions of the British public and those living with diabetes when it comes to stigma surrounding the condition.

Reference Page Path
/content/corp/abbott/gb/en/media-center/news/brits-living-with-diabetes-feel-stigma-and-bias-impact-their-ability-to-manage-their-condition

News

Publish Date
2022-11-10 13:30
Heading

ABBOTT LAUNCHES NEW INTEGRATED DIGITAL SOLUTION FOR PEOPLE WITH DIABETES IN THE UK

Description

Abbott’s FreeStyle Libre® systems and Novo Nordisk’s smart connected insulin pens now work together to help people manage their diabetes in a simpler, more integrated way.

Reference Page Path
/content/corp/abbott/gb/en/media-center/news/Abbott-Launches-New-Integrated-Digital-Solution-for-People-with-Diabetes-in-the-UK.html

News

Publish Date
2022-11-03 13:30
Heading

THE UK’S FIRST REMOTE NEUROMODULATION PATIENT-CARE TECHNOLOGY FROM ABBOTT NOW AVAILABLE IN KEY CENTRES ACROSS COUNTRY

Description

Abbott’s NeuroSphere™ Virtual Clinic, The UK’s first   remote neuromodulation patient-care technology, is now available in six specialist centres across the UK.

Reference Page Path
/content/corp/abbott/gb/en/media-center/news/The-UK-s-First-Remote-Neuromodulation-Patient-Care-Technology-From-Abbott-Now-Available-In-Key-Centres-Across-Country.html

News

Publish Date
2022-09-20 13:30
Heading

NEW DATA SHOWS THAT ABBOTT’S FREESTYLE LIBRE® SYSTEM REDUCES DIABETES-RELATED HOSPITALISATIONS FOR PEOPLE WITH TYPE 2 DIABETES ON ONCE-DAILY INSULIN THERAPY

Description

Abbott today announced new data from the Real World Evidence of FreeStyle Libre (RELIEF) study showing the use of the FreeStyle Libre continuous glucose monitoring system (CGM) significantly reduced the rate of hospitalisations due to acute diabetes events (ADEs) for people living with type 2 diabetes on once-daily (basal) insulin therapy.

Reference Page Path
/content/corp/abbott/gb/en/media-center/news/new-data-shows-that-abbotts-freestyle-libre-system-reduces-diabetes-related-hospitalisations-for-people-with-type-2-diabetes-on-once-daily-insulin-therapy.html

News

Publish Date
2022-04-28 00:00
Heading
NEW ANALYSIS SHOWS THAT ABBOTT’S FREESTYLE® LIBRE SYSTEM PROVIDES SIMILAR AND SUSTAINED REDUCTIONS IN GLUCOSE LEVELS FOR PEOPLE WITH BOTH TYPE 1 AND TYPE 2 DIABETES
Description
Abbott today announced results from a new meta-analysis of 75 real-world, observational studies demonstrating that its FreeStyle® Libre system provides significant reductions in glycated haemoglobin (HbA1c) that are sustained over up to 24 months in adults with both type 1 and type 2 diabetes.1
Reference Page Path
/content/corp/abbott/gb/en/media-center/news/new-analysis-shows-that-abbotts-freestyle-libre-system-provides-similar-and-sustained-reductions-in-glucose-levels-for-people-with-both-type-1-and-type-2-diabetes.html

News

Publish Date
2022-04-27 00:00
Heading
ABBOTT, CAMDIAB AND YPSOMED UNVEIL NEW AUTOMATED INSULIN DELIVERY PARTNERSHIP FOR PEOPLE WITH DIABETES
Description
Abbott, CamDiab and Ypsomed today announced that they are partnering to develop and commercialise an integrated automated insulin delivery (AID) system to help lessen the burden of round-the-clock diabetes management for people with diabetes.
Reference Page Path
/content/corp/abbott/gb/en/media-center/news/abbott-camdiab-and-ypsomed-unveil-new-automated-insulin-delivery-partnership-for-people-with-diabetes.html

News

Publish Date
2022-03-15 13:30
Heading
MODERN GLUCOSE MEASUREMENT WITH THE SMALLEST AND THINNEST SENSOR IN THE WORLD: ABBOTT'S FREESTYLE LIBRE 3 NOW AVAILABLE FOR USE IN THE UK
Description
Abbott, the global healthcare company, today announced that its FreeStyle Libre 3 continuous glucose monitoring (CGM) system, the latest addition to the world-leading FreeStyle Libre sensor technology, is now available for use in the UK.
Reference Page Path
/content/corp/abbott/gb/en/media-center/news/modern-glucose-measurement-with-the-smallest-and-thinnest-sensor-in-the-world.html

News

Publish Date
2021-12-03 13:30
Heading
ABBOTT RECEIVES CE MARK FOR FIRST WIDELY AVAILABLE LAB-BASED BLOOD TEST FOR TRAUMATIC BRAIN INJURY, INCREASING ACCESS TO CONCUSSION EVALUATION
Description
Abbott has received CE Mark for a laboratory traumatic brain injury (TBI) blood test, which will be the first widely available and will help clinicians assess individuals with suspected mild TBIs, including concussions. The test will run on Abbott’s Alinity™ i laboratory instrument, which produces a result within 18 minutes.
Reference Page Path
/content/corp/abbott/gb/en/media-center/news/abbott-receives-CE-Mark-for-first-widely-available-lab-based-blood-test-for-traumatic-brain-injury-increasing-access-to-concussion-evaluation.html

News

Publish Date
2021-12-03 13:30
Heading
ABBOTT ACHIEVES CE MARK FOR THE FIRST RAPID HANDHELD BLOOD PLASMA TEST FOR CONCUSSIONS
Description
Abbott has achieved CE Mark for the i-STAT TBI Plasma test, the first rapid handheld traumatic brain injury (TBI) blood plasma test, which permits marketing in the European Union and will help clinicians assess individuals with suspected mild TBIs, including concussions.
Reference Page Path
/content/corp/abbott/gb/en/media-center/news/abbott-achieves-CE-Mark-for-the-first-rapid-handheld-blood-plasma-test-for-concussions.html

News

Publish Date
2021-11-22 13:30
Heading
ABBOTT INTRODUCES NEUROSPHERE VIRTUAL CLINIC, FIRST-OF-ITS-KIND REMOTE NEUROMODULATION PATIENT-CARE TECHNOLOGY IN THE UK
Description
Airborne illnesses beyond COVID-19 and influenza must be part of prevention strategies in care homes to reduce hospitalisation of residents this winter, according to healthcare company Abbott.
Reference Page Path
/content/corp/abbott/gb/en/media-center/news/abbott-introduces-neuroSphere-virtual-clinic-first-of-its-kind-remote-neuromodulation-patient-care-technology-in-the-UK.html

News

Publish Date
2021-11-15 13:30
Heading
ROBUST TESTING FOR AIRBORNE ILLNESSES URGED ACROSS THE CARE INDUSTRY THIS WINTER TO PROTECT RESIDENTS AND STAFF
Description
Airborne illnesses beyond COVID-19 and influenza must be part of prevention strategies in care homes to reduce hospitalisation of residents this winter, according to healthcare company Abbott.
Reference Page Path
/content/corp/abbott/gb/en/media-center/news/robust-testing-for-airborne-illnesses-urged-across-the-care-industry-this-winter-to-protect-residents-and-staff.html

News

Publish Date
2021-09-30 00:00
Heading
REAL-WORLD DATA SHOW ABBOTT'S FREESTYLE LIBRELINK APP USERS SPEND MORE TIME IN TARGET GLUCOSE RANGE COMPARED TO READER USERS
Description
Abbott this week announced new data recently published in the Journal of Diabetes Science and Technology demonstrating that people living with diabetes who use FreeStyle Libre's smartphone app (versus a reader) experienced an average 5% (approximately an hour per day) more time spent in the target glucose range, known as Time in Range (TIR).
Reference Page Path
/content/corp/abbott/gb/en/media-center/news/real-world-data-show-abbotts-freestyle-librelink-app-users-spend-more-time-in-target-glucose-range-compared-to-reader-users.html

News

Publish Date
2021-06-29 13:30
Heading
ABBOTT'S PANBIO™ RAPID ANTIGEN SELF-TEST RECEIVES CE MARK, INCREASING ACCESS TO FAST, RELIABLE COVID-19 TESTING IN THE UNITED KINGDOM
Description
Abbott announced today it has received CE Mark for its Panbio™ COVID-19 Antigen Self-Test for sale direct-to-consumers for use in the detection of the SARS-CoV-2 virus in adults and children with or without symptoms. The approval paves the way for critical access to fast, reliable self-testing throughout the United Kingdom (UK) and Europe to reduce the spread of infection as economies reopen and daily life activities resume.
Reference Page Path
/content/corp/abbott/gb/en/media-center/news/abbotts-panbio-rapid-antigen-self-test-receives-ce-mark-increasing-access-to-fast-reliable-covid-19-testing-in-the-united-kingdom.html

News

Publish Date
2021-04-29 00:00
Heading
ABBOTT'S PANBIO™ RAPID ANTIGEN TEST NOW HAS A CE MARK FOR USE ON CHILDREN; FIRST RAPID ANTIGEN TEST WITH PERFORMANCE DATA ON CHILDREN
Description
Abbott announced today it now has a CE Mark for use of its Panbio™ COVID-19 Ag Rapid Test Device to detect the SARS-COV-2 virus in children age 15 years and younger. The CE Mark is based on the first-ever study focused on the performance of a rapid antigen test on children, including infants.
Reference Page Path
/content/corp/abbott/gb/en/media-center/news/abbotts-panbio-rapid-antigen-test-now-has-a-CE-mark-for-use-on-children-first-rapid-antigen-test-with-performance-data-on-children.html

News

Publish Date
2021-04-26 14:39
Heading
ABBOTT'S NEW CORONARY IMAGING PLATFORM POWERED BY ARTIFICIAL INTELLIGENCE LAUNCHES IN EUROPE
Description
Abbott today announced that its new imaging platform powered by Ultreon 1.0 Software, is now CE Marked in Europe.
Reference Page Path
/content/corp/abbott/gb/en/media-center/news/abbotts-new-coronary-imaging-platform-powered-by-artificial-intelligence-launches-in-europe.html

News

Publish Date
2021-03-11 13:30
Heading
ABBOTT ANNOUNCES ITS PANDEMIC DEFENCE COALITION: A GLOBAL NETWORK OF EXPERT COLLABORATORS DESIGNED TO HELP PREVENT FUTURE PANDEMICS, CURRENTLY SEARCHING FOR COVID-19 VARIANTS
Description
We've launched the Abbott Pandemic Defense Coalition, aiming to help prevent viral threats from reaching pandemic levels and identify new COVID-19 variants.
Reference Page Path
/content/corp/abbott/gb/en/media-center/news/pandemic-defense-coalition-to-help-prevent-future-threats.html

News

Publish Date
2021-03-02 14:39
Heading
ABBOTT RESEARCHERS FIND RARE GROUP OF PEOPLE WITH CONTROLLED HIV WHO COULD BE A KEY TO UNLOCKING CURE
Description
A large group known as HIV controllers has been identified by Abbott Virus Hunters in the Democratic Republic of Congo. They may help us understand natural HIV suppression.
Reference Page Path
/content/corp/abbott/gb/en/media-center/news/Abbott-researchers-find-rare-group-of-people-with-controlled-HIV-who-could-be-a-key-to-unlocking-cure.html

News

Publish Date
2021-01-29 14:39
Heading
RESEARCH REVEALS MENTAL HEALTH IMPACT ON FAMILIES OF CHILDHOOD DIABETES DIAGNOSIS
Description
Abbott today releases findings of two research surveys, undertaken before and during the COVID-19 pandemic, examining how a childhood Type 1 diabetes (T1D) diagnosis affects the emotional and mental health of children and their families. The research also reveals the impact of managing the condition with the added pressure of the COVID-19 outbreak.
Reference Page Path
/content/corp/abbott/gb/en/media-center/news/research-reveals-mental-health-impact-on-families-of-childhood-diabetes-diagnosis.html

News

Publish Date
2021-01-28 14:39
Heading
ABBOTT DONATES 10,000 ADDITIONAL FREESTYLE LIBRE SENSORS FOR UK HOSPITAL PATIENTS WITH DIABETES DURING COVID-19 PANDEMIC PEAK
Description
Abbott announced today that it will donate a further 10,000 FreeStyle Libre sensors to support patients with diabetes who use insulin and are admitted to UK hospitals during the COVID-19 pandemic. NHS Trusts can now make applications directly to Abbott to access this allocation of the world’s leading1 sensor-based glucose monitoring technology.
Reference Page Path
/content/corp/abbott/gb/en/media-center/news/abbott-donates-10000-additional-freestyle-libre-sensors.html

News

Publish Date
2021-01-26 14:39
Heading
ABBOTT'S PANBIO RAPID ANTIGEN TEST RECEIVES CE MARK FOR ASYMPTOMATIC SCREENING AND SELF-ADMINISTERED SAMPLE COLLECTION WITH NASAL SWAB
Description
Abbott announced today it has received CE Mark for two new uses of its Panbio™ COVID-19 Ag Rapid Test Device for the detection of the SARS-CoV-2 virus: asymptomatic testing and self-swabbing.
Reference Page Path
/content/corp/abbott/gb/en/media-center/news/abbotts-panbio-rapid-antigen-test-receives-ce-mark-for-asymptomatic-screening-and-self-administered-sample-collection-with-nasal-swab.html

News

Publish Date
2020-12-16 14:12
Heading
ABBOTT RECEIVES CE MARK FOR ITS COVID-19 IGG QUANTITATIVE ANTIBODY BLOOD TEST
Description
Abbott has received CE Mark for its new quantitative SARS-CoV-2 IgG (Immunoglobulin G) lab-based serology test.
Reference Page Path
/content/corp/abbott/gb/en/media-center/news/abbott-receives-ce-mark-for-its-COVID-19-IgG-quantitative-antibody-blood-test.html

News

Publish Date
2020-12-15 14:12
Heading
ABBOTT OBTAINS CE MARK FOR LABORATORY PCR ASSAY THAT DETECTS SARS-COV-2, FLU A, FLU B, AND RSV IN ONE TEST
Description
Abbott announced CE Mark for the company's Alinity™ m Resp-4-Plex molecular assay to detect and differentiate SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV) in one test.
Reference Page Path
/content/corp/abbott/gb/en/media-center/news/abbott-obtains-ce-mark-for-laboratory-pcr-assay-that-detects-SARS-CoV-2-Flu-A-Flu-B-and-RSV-in-one-test.html

News

Publish Date
2020-12-10 14:12
Heading
ABBOTT SECURES THREE LEADING UK WORKPLACE ACCOLADES INCLUDING TOP 10 BEST WORKPLACE FOR WOMEN IN 2020
Description
Global healthcare leader Abbott has been awarded three prestigious accolades reflecting its working culture and commitment to UK employees, including ranking in Britain's top 10 Best Workplace for Women for 2020.
Reference Page Path
/content/corp/abbott/gb/en/media-center/news/abbott-secures-three-leading-uk-workplace-accolades-including-top-10-best-workplace-for-women-in-2020.html

News

Publish Date
2020-09-28 14:39
Heading
ABBOTT'S FREESTYLE® LIBRE 3 SYSTEM RECEIVES CE MARK – FEATURES WORLD'S SMALLEST, THINNEST SENSOR WITH BEST-IN- CLASS PERFORMANCE AT THE SAME LOW COST FOR PEOPLE WITH DIABETES
Description
Abbott, the worldwide leader in continuous glucose monitoring (CGM) technology, announced today it has secured CE Mark (Conformité Européenne) for its next-generation FreeStyle Libre 3 system, which is now approved for use by people living with diabetes in Europe.
Reference Page Path
/content/corp/abbott/gb/en/media-center/news/abbotts-freestyle-libre-3-system-receives-ce-mark.html

News

Publish Date
2020-05-27 13:54
Heading
STATEMENT FROM ABBOTT ON USE OF ABBOTT’S ARCHITECT SARS-COV-2 ANTIBODY TEST WITH HOME KITS
Description
27th May, 2020 — We understand we live in unprecedented times, where the demand for self-sample collection solutions for testing is high, but Abbott has not currently validated our SARS-CoV-2 laboratory tests for self-sample collection procedures, such as finger stick (capilliary) blood.
Reference Page Path
/content/corp/abbott/gb/en/media-center/news/statement-from-abbott-on-use-of-Abbott-Architect-SARS-COV-2-antibody-test-with-home-kits.html

News

Publish Date
2020-05-21 14:12
Heading
ABBOTT ANNOUNCES CONTRACT TO SUPPLY MILLIONS OF IGG LAB-BASED ANTIBODY TESTS TO THE UK GOVERNMENT
Description
21st May, 2020 — Abbott announced a government contract to supply millions of its laboratory-based IgG antibody tests to NHS laboratories across the UK over the coming months. Abbott has already shipped 800,000 antibody tests this week to NHS laboratories, to be used as part of the testing initiative announced by the Secretary of State for Health today.
Reference Page Path
/content/corp/abbott/gb/en/media-center/news/abbott-announces-contract-to-supply-millions-of-IgG-lab-based-antibody-tests-to-the-UK-government.html

Cards to display on load -->

6

Showing text -->

Showing 1 - {} of {}

load more text -->

SHOW MORE